^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC).

Published date:
02/08/2021
Excerpt:
Results from TRITON2 showed antitumor activity for rucaparib in patients with BRCA+ mCRPC associated with or without co-occurring alterations in TP53.
DOI:
10.1200/JCO.2021.39.6_suppl.80
Trial ID: